Abstract
Patients with hemato-oncologic diseases are particularly vulnerable to severe infections. Adult patients with blood cancers infected with SARS-CoV-2 had poorer treatment outcomes and higher mortality than patients with COVID-19 without burden. However, in pediatric patients with hemato-oncologic diseases the course of COVID-19 is milder than in adults in the same group of patients. In this report, we describe the case of our patient with acute lymphoblastic leukemia infected with SARS-CoV-2 and treated with remdesivir. We also review the existing literature of pediatric patients who have been diagnosed with both hemato-oncologic diseases and COVID-19.
| Original language | English (US) |
|---|---|
| Pages (from-to) | E537-E538 |
| Journal | Journal of pediatric hematology/oncology |
| Volume | 44 |
| Issue number | 2 |
| DOIs | |
| State | Published - Mar 1 2022 |
Keywords
- COVID-19
- SARS-CoV-2
- acute lymphoblastic leukemia
- pediatrics
- remdesivir
- Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications
- COVID-19 Drug Treatment
- Prognosis
- COVID-19/complications
- SARS-CoV-2/isolation & purification
- Alanine/analogs & derivatives
- Humans
- Adenosine Monophosphate/analogs & derivatives
- Neoplasm Recurrence, Local/drug therapy
- Antiviral Agents/therapeutic use
- Female
- Child
ASJC Scopus subject areas
- Hematology
- Oncology
- Pediatrics, Perinatology, and Child Health